Our results demonstrate that AMPs inhibit NSCLC cell proliferation, migration, and invasion in part by downregulating CHRM3 and attenuating PI3K/AKT and MAPK signaling. The gene discussed is CHRM3; the disease is non-small cell lung carcinoma.